Ruben A. Mesa, MD, FACP, president and executive director of Atrium Health Levine Cancer Institute (LCI) and Atrium Health Wake Forest Baptist Comprehensive Cancer Center, discusses how practices can improve access and affordability to treatments for rare cancers, such as myeloproliferative neoplasms.
It is important that practices provide patients with a treatment structure that really helps support an individual with any type of cancer and meets their unique needs, says Ruben A. Mesa, MD, FACP, president and executive director of Atrium Health Levine Cancer Institute (LCI) and Atrium Health Wake Forest Baptist Comprehensive Cancer Center.
This transcript has been lightly edited for clarity.
Transcript
How can health care systems like Atrium Health effectively balance the treatment of rare diseases, such as myeloproliferative neoplasms, with more common types of cancer in their value-based care approaches?
As we learn more about precision cancer care—in many ways, every cancer is rare these days as we really look at the differences between patients, the different molecular mutations, different presentations, and issues regarding each individual patient—I think it starts with us really having a structure that helps to support the individual patient and their needs.
The prior days when we treated everyone with breast cancer the same as everyone with lung cancer; those days are long gone. So, I think as we have both the ability to support the full range of things in terms of being able to support clinical trials—more clinical trials, and more nimbly for smaller groups of patients—the ability to identify how patients are different and be able to support them is really crucial.
Given your extensive experience in developing FDA-approved drugs for chronic leukemias, what strategies do you believe are essential to ensure access to treatments for patients with rare cancers while remaining cost-effective?
One of the main drivers of approval for the FDA these days is really the clinical benefit to the patient. Drugs clearly have to have good data in terms of safety and effectiveness, as well as a strong rationale for their use in terms of mechanism of action and impact on the disease. FDA clearly looks at what is the overall benefit for the patient when one weighs risk and benefit.
And to some degree, I think as we look at the final piece, clinical benefit also includes the ability to access a medication. So, I think increasingly, that becomes an important piece—perhaps not the FDA regulatory piece, but broader in terms of our health care system piece. We can't have a great therapy that but then not have the patients who might benefit be able to receive that therapy. So that's another critical piece.
It clearly takes partnership between both the manufacturers of these medications and the many philanthropic groups around the country that make an important impact. I've been involved as a leader at the Leukemia Lymphoma Society, where they have worked hard to maintain access to critical therapies for patients with hematologic malignancies.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Kaiser Permanente was hit by a data breach in mid-April, impacting 13.4 million health plan members; GlaxoSmithKline (GSK) sued Pfizer and BioNTech for allegedly infringing on its messenger RNA technology patents in the companies’ COVID-19 vaccines; the CDC announced the first-known HIV cases transmitted via cosmetic injections.
Read More